Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted CLIA (Clinical Laboratory Improvement Amendments) Waiver for the Alere Determine™ HIV-1/2 Ag/Ab Combo test. Until now, the test has been available for s…
Source:Alere Determine HIV-1/2 Ag/Ab Combo test receives CLIA Waiver from FDA
Tuesday, December 9, 2014
Alere Determine HIV-1/2 Ag/Ab Combo test receives CLIA Waiver from FDA
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment